448 related articles for article (PubMed ID: 27466467)
1. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome.
Ariño H; Armangué T; Petit-Pedrol M; Sabater L; Martinez-Hernandez E; Hara M; Lancaster E; Saiz A; Dalmau J; Graus F
Neurology; 2016 Aug; 87(8):759-65. PubMed ID: 27466467
[TBL] [Abstract][Full Text] [Related]
2. Three cases of antibody-LGI1 limbic encephalitis and review of literature.
Bing-Lei W; Jia-Hua Z; Yan L; Zan Y; Xin B; Jian-Hua S; Hui-Juan W
Int J Neurosci; 2019 Jul; 129(7):642-648. PubMed ID: 30112956
[TBL] [Abstract][Full Text] [Related]
3. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity.
Malter MP; Frisch C; Schoene-Bake JC; Helmstaedter C; Wandinger KP; Stoecker W; Urbach H; Surges R; Elger CE; Vincent AV; Bien CG
J Neurol; 2014 Sep; 261(9):1695-705. PubMed ID: 24935858
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis.
Muñiz-Castrillo S; Haesebaert J; Thomas L; Vogrig A; Pinto AL; Picard G; Blanc C; Do LD; Joubert B; Berzero G; Psimaras D; Alentorn A; Rogemond V; Dubois V; Ambati A; Tamouza R; Mignot E; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33848259
[TBL] [Abstract][Full Text] [Related]
5. Natural course of LGI1 encephalitis: 3-5 years of follow-up without immunotherapy.
Szots M; Marton A; Kover F; Kiss T; Berki T; Nagy F; Illes Z
J Neurol Sci; 2014 Aug; 343(1-2):198-202. PubMed ID: 24928080
[TBL] [Abstract][Full Text] [Related]
6. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.
van Sonderen A; Thijs RD; Coenders EC; Jiskoot LC; Sanchez E; de Bruijn MA; van Coevorden-Hameete MH; Wirtz PW; Schreurs MW; Sillevis Smitt PA; Titulaer MJ
Neurology; 2016 Oct; 87(14):1449-1456. PubMed ID: 27590293
[TBL] [Abstract][Full Text] [Related]
7. Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study.
Sabanathan S; Abdel-Mannan O; Mankad K; Siddiqui A; Das K; Carr L; Eltze C; Eyre M; Gadian J; Hemingway C; Kaliakatsos M; Kneen R; Krishnakumar D; Lynch B; Parida A; Rossor T; Taylor M; Wassmer E; Wright S; Lim M; Hacohen Y
Ann Clin Transl Neurol; 2022 Jan; 9(1):67-78. PubMed ID: 35015932
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
[TBL] [Abstract][Full Text] [Related]
9. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy.
Shin YW; Lee ST; Shin JW; Moon J; Lim JA; Byun JI; Kim TJ; Lee KJ; Kim YS; Park KI; Jung KH; Lee SK; Chu K
J Neuroimmunol; 2013 Dec; 265(1-2):75-81. PubMed ID: 24176648
[TBL] [Abstract][Full Text] [Related]
10. LGI1 antibody encephalitis: acute treatment comparisons and outcome.
Rodriguez A; Klein CJ; Sechi E; Alden E; Basso MR; Pudumjee S; Pittock SJ; McKeon A; Britton JW; Lopez-Chiriboga AS; Zekeridou A; Zalewski NL; Boeve BF; Day GS; Gadoth A; Burkholder D; Toledano M; Dubey D; Flanagan EP
J Neurol Neurosurg Psychiatry; 2022 Mar; 93(3):309-315. PubMed ID: 34824144
[TBL] [Abstract][Full Text] [Related]
11. A Patient with Limbic Encephalitis Associated with Anti-leucine-rich Glioma-inactivated 1 (LGI1) Antibody Presenting with Slowly Progressive Cognitive Impairment and Fluctuating Striatal Lesions.
Sato M; Kishida D; Miyazaki D; Sekijima Y
Intern Med; 2019 Jan; 58(2):287-291. PubMed ID: 30146575
[TBL] [Abstract][Full Text] [Related]
12. The Treatment and Follow-Up of Anti-LGI1 Limbic Encephalitis.
Yu J; Yu X; Fang S; Zhang Y; Lin W
Eur Neurol; 2016; 75(1-2):5-11. PubMed ID: 26694143
[TBL] [Abstract][Full Text] [Related]
13. Limbic encephalitis with LGI1 antibodies in a 14-year-old boy.
Schimmel M; Frühwald MC; Bien CG
Eur J Paediatr Neurol; 2018 Jan; 22(1):190-193. PubMed ID: 28919330
[TBL] [Abstract][Full Text] [Related]
14. LGI1 antibody-associated encephalitis without evidence of inflammation in CSF and brain MRI.
Jia Y; Wang H; Zhang M; Wei M; Huang Z; Ye J; Liu A; Wang Y
Acta Neurol Belg; 2023 Jun; 123(3):849-856. PubMed ID: 35527332
[TBL] [Abstract][Full Text] [Related]
15. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.
Vincent A; Buckley C; Schott JM; Baker I; Dewar BK; Detert N; Clover L; Parkinson A; Bien CG; Omer S; Lang B; Rossor MN; Palace J
Brain; 2004 Mar; 127(Pt 3):701-12. PubMed ID: 14960497
[TBL] [Abstract][Full Text] [Related]
16. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
Huang X; Fan C; Gao L; Li L; Ye J; Shen H
J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of nine cases of leucine-rich glioma inactivated 1 protein antibody-associated encephalitis.
Li Y; Song F; Liu W; Wang Y
Acta Neurol Belg; 2021 Aug; 121(4):889-897. PubMed ID: 32232701
[TBL] [Abstract][Full Text] [Related]
18. The importance of early immunotherapy in patients with faciobrachial dystonic seizures.
Thompson J; Bi M; Murchison AG; Makuch M; Bien CG; Chu K; Farooque P; Gelfand JM; Geschwind MD; Hirsch LJ; Somerville E; Lang B; Vincent A; Leite MI; Waters P; Irani SR;
Brain; 2018 Feb; 141(2):348-356. PubMed ID: 29272336
[TBL] [Abstract][Full Text] [Related]
19. Anti-LGI1 encephalitis causing faciobrachial dystonic seizures.
Zouras S; Stephens JW; Abburu SR; Emelle C
BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29103007
[TBL] [Abstract][Full Text] [Related]
20. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.
Gadoth A; Pittock SJ; Dubey D; McKeon A; Britton JW; Schmeling JE; Smith A; Kotsenas AL; Watson RE; Lachance DH; Flanagan EP; Lennon VA; Klein CJ
Ann Neurol; 2017 Jul; 82(1):79-92. PubMed ID: 28628235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
